Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QuantumSi Inc (QSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: QSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.34% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 254.57M USD | Price to earnings Ratio - | 1Y Target Price 3.38 |
Price to earnings Ratio - | 1Y Target Price 3.38 | ||
Volume (30-day avg) 9830973 | Beta 2.79 | 52 Weeks Range 0.61 - 5.77 | Updated Date 03/27/2025 |
52 Weeks Range 0.61 - 5.77 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-26 | When After Market | Estimate -0.19 | Actual -0.1636 |
Profitability
Profit Margin - | Operating Margin (TTM) -2584.56% |
Management Effectiveness
Return on Assets (TTM) -24.85% | Return on Equity (TTM) -41.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57915978 | Price to Sales(TTM) 83.25 |
Enterprise Value 57915978 | Price to Sales(TTM) 83.25 | ||
Enterprise Value to Revenue 18.94 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 163207008 | Shares Floating 147077585 |
Shares Outstanding 163207008 | Shares Floating 147077585 | ||
Percent Insiders 14.83 | Percent Institutions 29.05 |
Analyst Ratings
Rating 3.5 | Target Price 3.25 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
QuantumSi Inc
Company Overview
History and Background
Quantum-Si Incorporated, founded in 2013, focuses on developing a next-generation protein sequencing platform. Initially named Erisyon, the company merged with HighCape Capital Acquisition Corp. in June 2021 to become Quantum-Si Incorporated, trading on the Nasdaq. Their aim is to democratize access to protein sequencing, enabling researchers and clinicians to gain deeper insights into biology.
Core Business Areas
- Protein Sequencing Instruments: Develops and sells its Platinum protein sequencing platform and related consumables.
- Data Analysis Software: Provides software tools for analyzing protein sequencing data generated by its instruments.
Leadership and Structure
Dr. Jonathan Rothberg, a serial entrepreneur in genomics, is a co-founder. The company has a board of directors and a management team overseeing operations, research and development, sales, and marketing. The organizational structure follows a functional model.
Top Products and Market Share
Key Offerings
- Platinum: Quantum-Si's Platinum is a next-generation protein sequencing platform that uses semiconductor chip technology to analyze proteins at the single-molecule level. Market share is emerging. Key competitors include traditional proteomics methods such as mass spectrometry offered by companies like Thermo Fisher Scientific (TMO).
- Consumables: Quantum-Si sells consumables specific to its Platinum platform, including reagents and flow cells. Revenue is directly tied to Platinum instrument usage. Competitors are any providing reagents for other platforms.
Market Dynamics
Industry Overview
The proteomics market is growing, driven by advancements in technology and increasing demand for protein-based diagnostics and therapeutics. Protein sequencing, in particular, is attracting significant investment and innovation.
Positioning
Quantum-Si aims to disrupt the proteomics market with its single-molecule protein sequencing technology, offering advantages in speed, cost, and accessibility compared to traditional methods.
Total Addressable Market (TAM)
The proteomics market is estimated to be in the billions of dollars. Quantum-Si is positioned to capture a portion of this market by offering a novel protein sequencing solution.
Upturn SWOT Analysis
Strengths
- Proprietary protein sequencing technology
- Potential to disrupt the proteomics market
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited commercial track record
- High operating expenses
- Dependence on successful product launch
- Competition from established proteomics companies
Opportunities
- Expanding into new applications, such as drug discovery and diagnostics
- Partnerships with pharmaceutical companies and research institutions
- Increasing adoption of protein sequencing in research and clinical settings
- Developing new assays and consumables for the Platinum platform
Threats
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn
- Failure to gain market acceptance
Competitors and Market Share
Key Competitors
- TMO
- DANO
- ILMN
Competitive Landscape
Quantum-Si competes with established players in proteomics and genomics. Its advantages include its proprietary technology and potential to disrupt the market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not yet applicable due to the company's early commercial stage.
Future Projections: Future projections depend on successful product adoption and market penetration. Analyst estimates vary widely.
Recent Initiatives: Focus on commercial launch of Platinum, expanding sales and marketing efforts, and developing new applications.
Summary
Quantum-Si is a high-risk, high-reward investment in the emerging field of protein sequencing. While its technology holds promise, the company faces significant challenges in gaining market acceptance and competing with established players. Investors should carefully consider the risks and potential rewards before investing. A successful product launch and continued innovation will be crucial for its long-term success.
Similar Companies
- PACB
- ONT
- TMO
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data, which may be subject to change. Investments in emerging technology companies carry significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About QuantumSi Inc
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-10 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.